Diligence report Healthcare & Life Sciences; AI-powered clinical care coordination and medical imaging workflow software Private unicorn / growth-stage healthcare AI platform

Viz.ai

Viz.ai Startup Diligence Report

Proceed to confirmatory diligence only if Viz.ai can prove that regulated AI care coordination converts large hospital and life-science footprint into durable, profitable ARR while maintaining FDA/PHI/AI-governance compliance and differentiation against other clinical AI platforms.

Company profile

Viz.ai Startup Diligence Report

Viz.ai has credible public support for unicorn status, major financing, FDA-regulated product milestones, broad product/partner footprint and visible leadership. Public evidence is not sufficient to conclude investment quality because financials, customer ARR/retention, cap table, contracts, IP, detailed regulatory files and HR data are private.

Website: www.viz.ai
Sector: Healthcare & Life Sciences; AI-powered clinical care coordination and medical imaging workflow software
Geography: United States / San Francisco with public operating locations in Tel Aviv, Portugal and Amsterdam
Stage: Private unicorn / growth-stage healthcare AI platform
Known aliases: Viz.ai, Viz.ai, Inc., Viz.AI, Viz AI, Viz Platform, Viz.ai One
Report version: 1.0
Timezone: UTC

Executive summary

Strengths

Unicorn valuation/date is supported by CB Insights row and Series D announcement.
Series C and Series D amounts and investor participation are publicly supported.
FDA 2018 De Novo authorization and product IFU boundaries are public.

Risks

Financial statements, cap table and current valuation support are private.
Regulated SaMD products and agentic workflows create clinical safety/FDA risk.
Customer ARR concentration, retention and contract quality are unknown.

Gaps

Audited financials, KPI pack, cap table, option pool and financing terms.
Customer ARR concentration, NRR/churn, reference calls and module utilization.
FDA clearance inventory, QMS, adverse-event/post-market files and reimbursement history.
Material contracts, partner economics, data rights, BAAs, SOC/ISO artifacts and insurance.
IP/source-code ownership, open-source SBOM, HRIS headcount/attrition and compensation/equity plans.

Recommended next steps

Open financial/cap-table/customer data room before relying on valuation or profitability claims.
Run regulatory, security and AI-governance specialist reviews with customer and technical references.
Benchmark against RapidAI, Aidoc, Qure.ai and Brainomix using matched workflows, pricing and outcomes.
Have counsel run full litigation/IP/contract searches and review FDA/CMS/privacy records.

Risk register

high medium likelihood

R-001: Financial statements and valuation support are private

The $1.2B valuation is public, but financials, cash, debt, ARR and cap table are not.

Diligence request: Request financials, KPI pack, forecast, cap table and financing documents.

high medium likelihood

R-003: Regulated SaMD and clinical-safety boundary risk

IFUs limit products to triage/notification support; model updates or marketing beyond cleared scope could create exposure.

Diligence request: Obtain FDA matrix, labeling, QMS, validation and post-market surveillance.

high medium likelihood

R-006: PHI/security/privacy and AI governance exposure

Viz.ai processes PHI at scale and launches agentic AI workflows; audit artifacts were not reviewed.

Diligence request: Review SOC 2, ISO, HIPAA, subprocessors, incidents and AI monitoring.

high medium likelihood

R-011: Regulatory/reimbursement change exposure

FDA, CMS, privacy and AI governance requirements could affect adoption and economics.

Diligence request: Review reimbursement history, CMS exposure, regulatory roadmap and international readiness.

high unknown likelihood

R-002: Customer concentration and retention unknown

Hospital counts and logos do not disclose ARR concentration, renewal terms, NRR, churn or deployment depth.

Diligence request: Request customer ARR, contracts, renewal cohorts, usage and references.

medium high likelihood

R-004: Competitive pressure from clinical AI platforms

RapidAI, Aidoc, Qure.ai and Brainomix market overlapping clinical AI and imaging workflow solutions.

Diligence request: Run win/loss, price and implementation benchmark.

medium medium likelihood

R-005: Company-reported scale claims need corroboration

2,000 hospitals, 230M lives, profitability and outcomes are primarily company-reported.

Diligence request: Reconcile customer master, telemetry, financials and references.

medium medium likelihood

R-007: Life-sciences partner economics and conflicts not public

Life-science partnerships may add revenue and compliance complexity, but terms and concentration are not disclosed.

Diligence request: Request partner contracts, revenue by partner, data rights and compliance review.

Chapter 01

01Financial Information

Public evidence supports unicorn/financing history but not financial quality, cap table or valuation support.

EC-001 EC-002 EC-003 EC-004 EC-027

I.A Annual and quarterly financial information for the past three years

not publicly verifiable confidence: high

No audited financial statements, management reports, backlog or AR aging are public.

EC-004 EC-009 EC-027

Evidence gaps

Private data-room evidence required where public sources are incomplete.

Hidden risks

R-001 remains open until private diligence closes this section.
R-002 remains open until private diligence closes this section.

Follow-up questions

Provide source records needed to close checklist section I.A.

Revenue and unit-economics signals
Metric	Public evidence	Status	Request
Healthcare profitability	Company-reported 2025	partially_verified	Audited P&L/cash-flow
Life-sciences growth	Doubled over 18 months; 13 partnerships	partially_verified	Revenue by partner
ARR/NRR/gross margin/pricing	Not public	not_publicly_verifiable	KPI pack, price book, cloud cost model

I.B Financial Projections

not publicly verifiable confidence: medium

Forecasts are not public; public growth drivers include hospitals, partnerships and product expansion.

EC-009 EC-015 EC-016 EC-025 EC-026

Evidence gaps

Private data-room evidence required where public sources are incomplete.

Hidden risks

R-001 remains open until private diligence closes this section.
R-007 remains open until private diligence closes this section.
R-011 remains open until private diligence closes this section.

Follow-up questions

Provide source records needed to close checklist section I.B.

Public valuation trajectory Valuation anchor and disclosure gaps

I.C Capital Structure

not publicly verifiable confidence: high

Investors and valuation are public; shares, preferences, warrants, debt and off-balance-sheet liabilities are private.

EC-001 EC-002 EC-003

Evidence gaps

Private data-room evidence required where public sources are incomplete.

Hidden risks

R-001 remains open until private diligence closes this section.

Follow-up questions

Provide source records needed to close checklist section I.C.

Capital structure and ownership snapshot
Stakeholder	Public position	Evidence	Diligence caveat
Founders	Mansi/Golan founded Viz.ai in 2016	Our Story / leadership	Ownership and IP assignments private
Growth investors	Tiger/Insight led Series D; Scale, Kleiner, Threshold, CRV participated	Financing releases/CB row	Share classes private
HCA Healthcare	Customer and investor named	Series D	Related-party terms unknown

I.D Other financial information

partially verified confidence: high

Series C and Series D are publicly supported; tax, accounting policies and complete financing history are private.

EC-001 EC-002 EC-003

Evidence gaps

Private data-room evidence required where public sources are incomplete.

Hidden risks

R-001 remains open until private diligence closes this section.

Follow-up questions

Provide source records needed to close checklist section I.D.

Public funding-round history
Date	Round/event	Amount	Valuation	Investors	Caveat
2021-03-17	Series C	$71M	Not disclosed	Scale, Insight, Greenoaks, Kleiner, Threshold, CRV, Innovation Endeavors, Susa	Terms private
2022-04-07	Series D	$100M	$1.2B	Tiger Global, Insight, Scale, Kleiner, Threshold, GV, Sozo, CRV, Susa	Preferences/cap table private
2026-06-03	CB Insights row	n/a	$1.20B latest known	Kleiner Perkins, CRV, Threshold	Market database value

Funding and strategic milestone timeline Public financing and milestone chronology

Chapter 02

02Products

Viz.ai has broad public product and regulatory claims, but pricing, module economics and full clearance inventory require diligence.

EC-005 EC-006 EC-007 EC-008 EC-018 EC-025 EC-026 EC-027

II.A Description of each product

partially verified confidence: medium

Public materials support the platform, suites and IFU limitations; architecture, pricing and product economics are private.

EC-005 EC-006 EC-007 EC-008 EC-018 EC-025 EC-026 EC-027

Evidence gaps

Private data-room evidence required where public sources are incomplete.

Hidden risks

R-003 remains open until private diligence closes this section.
R-004 remains open until private diligence closes this section.
R-008 remains open until private diligence closes this section.

Follow-up questions

Provide source records needed to close checklist section II.A.

Product and SKU matrix
Product	Audience	Public claim	Status	Need
Viz.ai One	Health systems	One platform, EHR/PACS workflows	partially_verified	Architecture/SLA review
Neuro suite	Stroke/neuro teams	LVO, CTP, hemorrhage, aneurysm, subdural	partially_verified	FDA/performance review
Vascular/Pulmonary	Vascular/pulmonary teams	Aortic, PE, COPD, nodules, Pulmonary Suite	partially_verified	Clinical evidence
Cardio/HCM	Cardiology	ECG HCM workflow	partially_verified	FDA/BMS files
Life Sciences/Agent Studio	Pharma/admins	Patient identification and custom AI care pathways	partially_verified	Contracts/AI governance

Pricing and packaging visibility
Vendor	Scope	Public pricing	Status	Request
Viz.ai	Enterprise platform	No public price list	not_publicly_verifiable	Price book/ACV
RapidAI	Clinical AI	No public price in fetched page	not_publicly_verifiable	Matched quote
Aidoc	Clinical AI/aiOS	Book demo; no public price	not_publicly_verifiable	Matched quote
Qure.ai / Brainomix	Imaging AI	No public price in snippets	not_publicly_verifiable	Benchmark

Regulatory/product indication matrix
Module	Role	Key limitation	Risk
Viz LVO	CTA brain LVO notification	Not diagnostic beyond notification	Labeling/use risk
ICH/SDH/Aneurysm	CT triage/notification	Preview images informational	False positives/negatives
RV-LV / PE & AD	Measurement/chest CTA triage	Use with professional judgment	Performance/provenance
HCM	ECG screening/follow-up	Does not confirm diagnosis	Bias/validation

Public product architecture Public-source abstraction of data, algorithms, workflow and integrations

Chapter 03

03Customer Information

Public evidence shows large adoption claims, named customers and partners, but ARR, concentration, churn and supplier economics are private.

EC-009 EC-015 EC-016 EC-017 EC-019

III.A Top customers by application

partially verified confidence: medium

Named customers and implementation examples exist publicly, but top-15 customers and purchase timing are private.

EC-009 EC-019

Evidence gaps

Private data-room evidence required where public sources are incomplete.

Hidden risks

R-002 remains open until private diligence closes this section.
R-005 remains open until private diligence closes this section.

Follow-up questions

Provide source records needed to close checklist section III.A.

Public customers and case studies
Customer	Use case/source	Status	Caveat
Mount Sinai/Thomas Jefferson/Banner/CommonSpirit	Named customers in Series D	partially_verified	ARR unknown
HCA Healthcare	Customer/investor; HCM research facilities	partially_verified	Related-party terms unknown
Piedmont Healthcare	11-hospital implementation	partially_verified	Contract not public
Cooper University Health Care	Public quotes	partially_verified	Economics unknown

Customer and partner scale anchors Public adoption and partner counts

III.B Strategic relationships

partially verified confidence: medium

Microsoft, Salesforce, BMS and life-science partnerships are public; economics and exclusivity are private.

EC-015 EC-016 EC-017

Evidence gaps

Private data-room evidence required where public sources are incomplete.

Hidden risks

R-007 remains open until private diligence closes this section.
R-008 remains open until private diligence closes this section.

Follow-up questions

Provide source records needed to close checklist section III.B.

Strategic relationships and partnerships
Partner	Nature	Evidence	Caveat
Microsoft	Precision Imaging Network	48+ models, 13 Viz algorithms, 17,000 facilities	Terms private
Salesforce	Workflow activation	Strategic partners page	Customers/terms private
BMS	HCM agreement	BMS and HCM releases	Economics private
Sanofi/Regeneron/Novartis/Guardant	Life-science partners	14 companies claim	Revenue private

III.C Revenue by customer

not publicly verifiable confidence: high

Revenue by customer and 5 percent concentration are not public.

EC-009 EC-019

Evidence gaps

Private data-room evidence required where public sources are incomplete.

Hidden risks

R-002 remains open until private diligence closes this section.

Follow-up questions

Provide source records needed to close checklist section III.C.

III.D Significant relationships severed within the last two years

not publicly verifiable confidence: medium

No public severed customer/partner/supplier schedule was found.

EC-004 EC-020

Evidence gaps

Private data-room evidence required where public sources are incomplete.

Hidden risks

R-002 remains open until private diligence closes this section.
R-010 remains open until private diligence closes this section.

Follow-up questions

Provide source records needed to close checklist section III.D.

III.E Top suppliers

partially verified confidence: medium

Public evidence identifies cloud/integration dependencies but not supplier spend or agreements.

EC-006 EC-013 EC-016 EC-025

Evidence gaps

Private data-room evidence required where public sources are incomplete.

Hidden risks

R-006 remains open until private diligence closes this section.
R-008 remains open until private diligence closes this section.

Follow-up questions

Provide source records needed to close checklist section III.E.

Supplier/cloud/infrastructure dependencies
Dependency	Role	Evidence	Risk	Request
Amazon/cloud tools	Cloud/monitoring	Trust center	Uptime/PHI/margin	Cloud contracts
Microsoft Azure/PowerShare	Channel/infrastructure	Microsoft release	Partner dependence	Contract/SLA
EHR/PACS vendors	Clinical integration	Viz.ai One/Pulmonary	Implementation friction	Integration matrix
Drata/trust center	Audit artifacts	Trust center	Scope risk	Access reports

Chapter 04

04Competition

Clinical AI competition is intense; public competitor pages show overlap but not market share or price advantage.

EC-005 EC-009 EC-021 EC-022 EC-023 EC-024 EC-027

IV.A Competitive landscape by market segment

partially verified confidence: medium

RapidAI, Aidoc, Qure.ai and Brainomix publicly market overlapping clinical AI capabilities.

EC-005 EC-009 EC-021 EC-022 EC-023 EC-024 EC-027

Evidence gaps

Private data-room evidence required where public sources are incomplete.

Hidden risks

R-004 remains open until private diligence closes this section.

Follow-up questions

Provide source records needed to close checklist section IV.A.

Competitor comparison matrix
Company	Overlap	Positioning	Risk
RapidAI	Clinical AI/neurovascular	Enterprise platform	Stroke workflow competition
Aidoc	Clinical AI/radiology	aiOS / IT integration	Enterprise AI budget competition
Qure.ai	Lung/TB/stroke AI	Accelerated healthcare	Global/disease overlap
Brainomix	Stroke/lung biomarkers	Imaging biomarkers	Stroke imaging competition

Basis-of-competition scoring
Axis	Viz.ai position	Pressure	Need
Workflow breadth	50+ algorithms, multi-suite	Aidoc/RapidAI platforms	Module attach benchmark
Evidence/regulatory	FDA/publication claims	Qure and others cite clearances	Normalize by indication
Distribution	2,000 hospitals plus Microsoft	Global/direct channels	Win/loss
Pricing/ROI	No public price	No matched public prices	TCO/ROI benchmark

Competitive positioning map Qualitative map of clinical AI competitors

Chapter 05

05Marketing, Sales, and Distribution

GTM appears to combine direct health-system sales, life-science partnerships and Microsoft/Salesforce channels; sales productivity is private.

EC-009 EC-015 EC-016 EC-017 EC-025 EC-026 EC-027

V.A Strategy and implementation

partially verified confidence: medium

Public strategy emphasizes enterprise care coordination, clinical evidence, awards and partner channels.

EC-009 EC-015 EC-016 EC-025 EC-027

Evidence gaps

Private data-room evidence required where public sources are incomplete.

Hidden risks

R-004 remains open until private diligence closes this section.
R-007 remains open until private diligence closes this section.

Follow-up questions

Provide source records needed to close checklist section V.A.

Distribution channels and GTM motions
Channel	Evidence	Buyer/user	Gap
Direct health-system sales	Nearly 2,000 hospitals	CIO/CMIO/service-line leaders	CAC/quota/cycle
Life-sciences partnerships	13-14 partners	Pharma/med-device	Revenue/compliance terms
Microsoft/PowerShare	17,000 facilities	Health systems using Microsoft/Nuance	Attach rate/reseller economics
Salesforce/Agentforce	Strategic partners page	Health systems/life sciences	Customer count/terms

Public marketing-signal summary
Signal	Evidence	Implication	Caveat
Clinical evidence	120+ publications/abstracts claimed	Clinical credibility	Quality review needed
Awards/rankings	Black Book #1, TIME, Edison cited	Sales credibility	Methodology unknown
Product launches	Assist/Oncology/Agent Studio/Pulmonary	Platform expansion	Adoption unknown
Partner PR	Microsoft/Salesforce/BMS/pharma	GTM leverage	Economics unknown

GTM channel count chart Public channel-scale anchors

V.B Major Customers

not publicly verifiable confidence: medium

Major-customer relationship trends, growth prospects and pipeline quality are not public.

EC-009 EC-019

Evidence gaps

Private data-room evidence required where public sources are incomplete.

Hidden risks

R-002 remains open until private diligence closes this section.
R-005 remains open until private diligence closes this section.

Follow-up questions

Provide source records needed to close checklist section V.B.

V.C Principal avenues for generating new business

partially verified confidence: medium

New business avenues include health-system sales, life sciences, Microsoft/PowerShare and Salesforce workflows.

EC-015 EC-016 EC-027

Evidence gaps

Private data-room evidence required where public sources are incomplete.

Hidden risks

R-007 remains open until private diligence closes this section.
R-008 remains open until private diligence closes this section.

Follow-up questions

Provide source records needed to close checklist section V.C.

V.D Sales force productivity model

not publicly verifiable confidence: high

Sales compensation, quota, cycle length and new-hire productivity are not public.

EC-011 EC-012

Evidence gaps

Private data-room evidence required where public sources are incomplete.

Hidden risks

R-001 remains open until private diligence closes this section.
R-009 remains open until private diligence closes this section.

Follow-up questions

Provide source records needed to close checklist section V.D.

V.E Ability to implement marketing plan with current and projected budgets

not publicly verifiable confidence: medium

Marketing budget sufficiency cannot be assessed from public PR cadence alone.

EC-009 EC-025 EC-026

Evidence gaps

Private data-room evidence required where public sources are incomplete.

Hidden risks

R-001 remains open until private diligence closes this section.
R-004 remains open until private diligence closes this section.

Follow-up questions

Provide source records needed to close checklist section V.E.

Chapter 06

06Research and Development

Public R&D signals include leadership, algorithms, publications and new launches; roadmap cost and validation files are private.

EC-005 EC-008 EC-011 EC-014 EC-017 EC-018 EC-025 EC-026

VI.A Description of R&D organization

partially verified confidence: medium

R&D, clinical and governance leaders are visible; detailed org, budget and staffing are private.

EC-011 EC-014 EC-025

Evidence gaps

Private data-room evidence required where public sources are incomplete.

Hidden risks

R-006 remains open until private diligence closes this section.
R-009 remains open until private diligence closes this section.

Follow-up questions

Provide source records needed to close checklist section VI.A.

Key R&D and clinical personnel
Name/role	Function	Evidence	Request
Oded Cohen, VP R&D and Israel GM	R&D leadership	Leadership page	R&D org/roadmap
Timothy Showalter, CMO	Clinical strategy	Leadership and Pulmonary release	Validation governance
Andrew Ibrahim, Chief Clinical Officer	Clinical adoption	Leadership page	Advisory process
David Kizner / Tom Vaknin	Legal/privacy/security/AI governance	Leadership and ISO release	Governance artifacts

R&D and clinical governance org chart Public R&D/clinical/security roles to diligence

VI.B New Product Pipeline

partially verified confidence: medium

Pipeline includes HCM, Viz Assist/Oncology, Agent Studio and Pulmonary Suite; cost, adoption and model performance are private.

EC-005 EC-008 EC-017 EC-018 EC-025 EC-026

Evidence gaps

Private data-room evidence required where public sources are incomplete.

Hidden risks

R-003 remains open until private diligence closes this section.
R-006 remains open until private diligence closes this section.
R-011 remains open until private diligence closes this section.

Follow-up questions

Provide source records needed to close checklist section VI.B.

Public product and R&D pipeline
Initiative	Status/date	Evidence	Risk
Viz HCM	BMS 2023; De Novo 2023	BMS/HCM releases	Partner economics/regulatory scope
Viz Assist/Oncology	2025 company-reported launches	Record-scale release	Adoption/monetization
Viz Agent Studio	2026-03-26	Agent Studio launch	Agentic AI safety/liability
Viz Pulmonary Suite	2026-05-14	Pulmonary launch	Evidence generalizability

Clinical evidence and regulatory anchors
Anchor	Public value	Status	Caveat
2018 Contact De Novo	FDA marketing authorization	verified	Decision summary needed
2021 LVO study cited	96% sensitivity, 94% specificity, 2,544 patients, 139 hospitals	partially_verified	Review full paper
2023 HCM status	Twelve algorithms, 1,400+ hospitals claimed	partially_verified	FDA file review
2026 evidence scale	120+ publications; 50+ algorithms claimed	partially_verified	Reconcile inventory

R&D evidence-scale trend Public algorithm/publication count anchors

Chapter 07

07Management and Personnel

Leadership and workforce signals are public, but HRIS, compensation, attrition and references are private.

EC-010 EC-011 EC-012 EC-014

VII.A Organization Chart

partially verified confidence: medium

Executives and board are public, but full organization chart is not.

EC-011

Evidence gaps

Private data-room evidence required where public sources are incomplete.

Hidden risks

R-009 remains open until private diligence closes this section.

Follow-up questions

Provide source records needed to close checklist section VII.A.

Senior management roster
Name	Role	Evidence	Request
Chris Mansi	CEO and Co-Founder	Leadership/Our Story	References/employment/IP
Jieun Choe / Oded Cohen	COO / VP R&D Israel GM	Leadership	Ops/R&D references
Jallel Harrati / Mike Herring	CRO / CFO	Leadership	Sales productivity/finance controls
Andrew Ibrahim / Timothy Showalter	Chief Clinical Officer / CMO	Leadership	Clinical governance
David Kizner / Dawn Sprague / Steve Sweeny	GC & CPO / VP People / CBO	Leadership	Legal/HR/BD controls

Public headcount trend Headcount anchors and current HRIS gap

VII.B Historical and projected headcount by function and location

partially verified confidence: medium

A 2022 headcount anchor is public; current function/location headcount is private.

EC-012

Evidence gaps

Private data-room evidence required where public sources are incomplete.

Hidden risks

R-009 remains open until private diligence closes this section.

Follow-up questions

Provide source records needed to close checklist section VII.B.

Headcount and hiring signals
Period	Public signal	Function/location	Gap
2021-2022	Grew from 180 to >350	San Francisco, Tel Aviv, Portugal, Amsterdam	Detailed mix private
2022 plan	Planned nearly 200 more hires	Clinical, product, engineering, business	Actual attainment private
2026 pages	Fully remote, benefits, open positions link	Remote; U.S./Israel benefits	Current HRIS private

VII.C Senior management biographies

partially verified confidence: medium

Senior management names and roles are public; full bios, compensation and references were not reviewed.

EC-010 EC-011

Evidence gaps

Private data-room evidence required where public sources are incomplete.

Hidden risks

R-009 remains open until private diligence closes this section.

Follow-up questions

Provide source records needed to close checklist section VII.C.

VII.D Compensation arrangements

not publicly verifiable confidence: medium

Benefits are public; key employment agreements and compensation are private.

EC-012

Evidence gaps

Private data-room evidence required where public sources are incomplete.

Hidden risks

R-009 remains open until private diligence closes this section.

Follow-up questions

Provide source records needed to close checklist section VII.D.

Turnover, compensation and employee-relations signals
Topic	Public signal	Status	Request
Executive appointments	Current roster visible	partially_verified	Tenure/predecessor departures
Employee relations	Remote work and benefits described	partially_verified	Attrition/claims
Compensation/equity	Benefits only; comp/equity private	not_publicly_verifiable	Employment agreements/option plan

VII.E Incentive stock plans

not publicly verifiable confidence: high

No public incentive stock plan, option pool or grant schedule was found.

EC-004

Evidence gaps

Private data-room evidence required where public sources are incomplete.

Hidden risks

R-001 remains open until private diligence closes this section.
R-009 remains open until private diligence closes this section.

Follow-up questions

Provide source records needed to close checklist section VII.E.

VII.F Significant employee relations problems, past or present

not publicly verifiable confidence: low

No employee-relations issue schedule was public.

EC-012 EC-020

Evidence gaps

Private data-room evidence required where public sources are incomplete.

Hidden risks

R-009 remains open until private diligence closes this section.
R-010 remains open until private diligence closes this section.

Follow-up questions

Provide source records needed to close checklist section VII.F.

VII.G Personnel Turnover

not publicly verifiable confidence: medium

Turnover data are not public; benefits are public but insufficient.

EC-012

Evidence gaps

Private data-room evidence required where public sources are incomplete.

Hidden risks

R-009 remains open until private diligence closes this section.

Follow-up questions

Provide source records needed to close checklist section VII.G.

Chapter 08

08Legal and Related Matters

Public regulatory/compliance milestones are meaningful; legal/IP/contracts/insurance require counsel-led diligence.

EC-007 EC-008 EC-013 EC-014 EC-018 EC-020 EC-028

VIII.A Pending lawsuits against the Company

inconclusive confidence: medium

CourtListener searches found no indexed Viz.ai results but are not comprehensive.

EC-020

Evidence gaps

Private data-room evidence required where public sources are incomplete.

Hidden risks

R-010 remains open until private diligence closes this section.

Follow-up questions

Provide source records needed to close checklist section VIII.A.

Lawsuits against company public search log
Source	Scope	Result	Limitation
CourtListener	"Viz.ai"	count 0	Not comprehensive
CourtListener	Viz.AI / Viz AI / Viz.ai Inc variants	count 0 in workstream	Variants/subsidiaries may be missed
Public company pages	Obvious litigation disclosure	None located	Private company no 10-K

VIII.B Pending lawsuits initiated by Company

inconclusive confidence: medium

No initiated-litigation results were found in limited public search.

EC-020 EC-028

Evidence gaps

Private data-room evidence required where public sources are incomplete.

Hidden risks

R-010 remains open until private diligence closes this section.

Follow-up questions

Provide source records needed to close checklist section VIII.B.

Lawsuits initiated by company public search log
Source	Scope	Result	Request
CourtListener	Viz.ai party variants	No indexed results found	Counsel PACER/state search
IP/trademark search attempts	Official disputes/oppositions	Not fully extracted	TTAB/PTAB/WIPO search
Data-room need	Demand letters/arbitration	Not public	Legal claims schedule

VIII.C Environmental and employee safety issues and liabilities

not publicly verifiable confidence: low

No public environmental or workplace-safety liabilities were found; software and clinical safety policies still require review.

EC-012 EC-013

Evidence gaps

Private data-room evidence required where public sources are incomplete.

Hidden risks

R-006 remains open until private diligence closes this section.
R-009 remains open until private diligence closes this section.

Follow-up questions

Provide source records needed to close checklist section VIII.C.

VIII.D Material patents, copyrights, licenses, and trademarks

not publicly verifiable confidence: low

Product marks are public but official IP ownership, assignments and licenses were not verified.

EC-028 EC-005

Evidence gaps

Private data-room evidence required where public sources are incomplete.

Hidden risks

R-010 remains open until private diligence closes this section.

Follow-up questions

Provide source records needed to close checklist section VIII.D.

Material IP and marks from public pages
Asset	Public evidence	Status	Request
Viz.ai / Viz.ai One	Brand/product pages	not_publicly_verifiable	USPTO/EUIPO/WIPO exports
Viz LVO/ICH/CTP/ANEURYSM/SDH/RV-LV/HCM	IFU headings use TM marks	not_publicly_verifiable	Trademark schedule
AI algorithms/source code/models	50+ algorithms claimed	not_publicly_verifiable	Patent/assignments/SBOM/data lineage
Viz Pulmonary / Agent Studio	2026 launch pages	not_publicly_verifiable	FTO and roadmap IP review

VIII.E Insurance coverage and material exposures

not publicly verifiable confidence: high

Cyber, E&O/product liability, D&O and claims history are not public.

EC-013 EC-007

Evidence gaps

Private data-room evidence required where public sources are incomplete.

Hidden risks

R-006 remains open until private diligence closes this section.
R-003 remains open until private diligence closes this section.
R-011 remains open until private diligence closes this section.

Follow-up questions

Provide source records needed to close checklist section VIII.E.

VIII.F Material contracts

not publicly verifiable confidence: high

Customer, partner, cloud, BAA, data-use and supplier contracts are not public.

EC-013 EC-015 EC-016 EC-017

Evidence gaps

Private data-room evidence required where public sources are incomplete.

Hidden risks

R-007 remains open until private diligence closes this section.
R-008 remains open until private diligence closes this section.
R-010 remains open until private diligence closes this section.

Follow-up questions

Provide source records needed to close checklist section VIII.F.

VIII.G Regulatory agency problems

partially verified confidence: medium

Public evidence includes FDA and compliance milestones; no public enforcement problem was found, but full agency history is incomplete.

EC-007 EC-008 EC-013 EC-014 EC-018 EC-020

Evidence gaps

Private data-room evidence required where public sources are incomplete.

Hidden risks

R-003 remains open until private diligence closes this section.
R-006 remains open until private diligence closes this section.
R-011 remains open until private diligence closes this section.

Follow-up questions

Provide source records needed to close checklist section VIII.G.

Regulatory and compliance actions
Date	Agency/standard	Action	Caveat
2018-02-13	FDA De Novo	Contact marketing authorization	Decision summary needed
2022 reference	CMS NTAP	Company says first AI software with NTAP approval	CMS rule history needed
2023-08-15	FDA De Novo	Viz HCM approval announced	FDA file needed
2026-05-05	ISO/IEC 42001	AI management-system certification announced	Certificate scope needed
Current	SOC 2/HIPAA/ISO privacy/security	Trust center lists certifications	Audit artifacts needed

Legal and regulatory timeline Public regulatory/compliance milestones and legal search gap

Risk heatmap Full diligence risk-register heatmap

Evidence

Evidence claims
ID	Claim	Status	Sources
EC-001	CB Insights row lists Viz.ai with latest known valuation $1.20B, joined 2022-04-07, San Francisco, Healthcare & Life Sciences, investors Kleiner Perkins, CRV and Threshold.	verified high	SRC-001
EC-002	Viz.ai announced a $100M Series D at a $1.2B valuation led by Tiger Global and Insight Partners with Scale, Kleiner Perkins, Threshold, GV, Sozo, CRV and Susa participating.	verified high	SRC-002
EC-003	Viz.ai announced a $71M Series C led by Scale Venture Partners and Insight Partners and said total funding exceeded $150M since inception.	verified high	SRC-003
EC-004	Audited financials, ARR, gross margin, cash/debt, cap table, backlog, AR aging and full financing terms are not public.	not publicly verifiable high	SRC-001 SRC-002 SRC-003 SRC-008
EC-005	Viz.ai publicly claims a care-coordination platform driven by more than 50 FDA-cleared AI algorithms across CT, EKG, echocardiogram and other data.	partially verified medium	SRC-004
EC-006	Viz.ai One is marketed as an AI-powered care coordination platform with real-time alerts, mobile/desktop workflow and EHR/PACS integration.	partially verified medium	SRC-005
EC-007	Viz.ai IFUs repeatedly limit modules to notification, triage or analysis support and warn that clinicians remain responsible for diagnosis and full patient evaluation.	verified high	SRC-006
EC-008	FDA permitted marketing of Viz.AI Contact in 2018 through De Novo pathway for stroke-alerting clinical decision support software.	verified high	SRC-007
EC-009	Viz.ai reported nearly 2,000 U.S. hospitals, majority of 50 largest health systems, more than 230M lives, healthcare-business profitability, 13 life-science partnerships and 120+ publications/abstracts.	partially verified medium	SRC-008
EC-010	Viz.ai says Chris Mansi and David Golan founded the company in 2016 to use AI to make healthcare faster and smarter.	verified medium	SRC-023
EC-011	Viz.ai publicly lists executives including Chris Mansi, Jieun Choe, Oded Cohen, Jallel Harrati, Mike Herring, Andrew Ibrahim, David Kizner, Timothy Showalter, Dawn Sprague and Steve Sweeny plus board members from Kleiner Perkins, UCSF Health, Threshold and Scale.	verified medium	SRC-009
EC-012	Viz.ai public workforce signals include fully remote work, benefits and a 2022 statement that headcount grew from 180 to more than 350 with plans to add nearly 200.	partially verified medium	SRC-010 SRC-002
EC-013	Viz.ai trust center claims SOC 2 Type II, HIPAA, ISO 27001/27701/27799/27017/27018/22301/27035 and PHI processing across 2,000 hospitals, with Amazon/cloud tools and Drata artifact access.	partially verified medium	SRC-011
EC-014	Viz.ai announced ISO/IEC 42001 AI management-system certification in May 2026 after an independent audit by an accredited certification body.	partially verified medium	SRC-012
EC-015	Viz.ai describes Salesforce, Microsoft and 14 life-science company partnerships including Sanofi, Regeneron, Novartis and Guardant Health.	partially verified medium	SRC-013
EC-016	Viz.ai announced Microsoft collaboration through Precision Imaging Network with 48+ AI models, 13 Viz algorithms, Azure, PowerShare and 17,000 connected healthcare facilities.	partially verified medium	SRC-014
EC-017	Viz.ai announced a multi-year BMS agreement for HCM workflow and later announced FDA De Novo approval for Viz HCM.	partially verified medium	SRC-015 SRC-016
EC-018	Viz HCM reviews routine ECGs for suspected HCM and notifies cardiologists; company said it was one of twelve FDA-cleared algorithms on a platform used across 1,400+ hospitals.	partially verified medium	SRC-016
EC-019	Public customer evidence includes Mount Sinai, Thomas Jefferson, Banner, CommonSpirit, HCA, Piedmont Healthcare and Cooper-related public quotes.	partially verified medium	SRC-002 SRC-017 SRC-004 SRC-025
EC-020	CourtListener public API searches returned zero results for Viz.ai variants in this workstream.	inconclusive medium	SRC-018
EC-021	RapidAI publicly positions as a clinical AI platform with enterprise workflow and neurovascular solutions.	verified medium	SRC-019
EC-022	Aidoc publicly positions as clinical AI solutions and an AI platform integrated into facility IT infrastructure.	verified medium	SRC-020
EC-023	Qure.ai publicly positions medical-imaging AI across lung cancer, TB and stroke and references FDA clearances.	verified medium	SRC-021
EC-024	Brainomix publicly positions AI-powered imaging biomarkers for stroke and lung care.	verified medium	SRC-022
EC-025	Viz.ai launched Viz Pulmonary Suite in May 2026 for COPD, lung nodules and PE workflows, with a single-center PE evidence caveat.	partially verified medium	SRC-024
EC-026	Viz.ai launched Viz Agent Studio in March 2026 for health systems to build and deploy AI care pathways using natural language.	partially verified medium	SRC-025
EC-027	Public pricing, discounts, realized ACV, gross margin by product, cloud cost and sales productivity are not disclosed.	not publicly verifiable high	SRC-004 SRC-005 SRC-013
EC-028	Official patents/trademarks, source-code ownership, assignment records and license obligations were not fully publicly verified; company pages show product marks.	not publicly verifiable low	SRC-004 SRC-006 SRC-024

Sources
ID	Publisher	Title	Accessed
SRC-001	CB Insights	CB Insights Complete List of Unicorn Companies	2026-06-03
SRC-002	Viz.ai	Viz.ai Raises $100 Million in Series D Funding	2026-06-03
SRC-003	Viz.ai	Viz.ai Raises $71 Million Series C Round	2026-06-03
SRC-004	Viz.ai	Viz.ai home page	2026-06-03
SRC-005	Viz.ai	Viz.ai One product page	2026-06-03
SRC-006	Viz.ai	Viz.ai Indications for Use	2026-06-03
SRC-007	U.S. Food and Drug Administration	FDA permits marketing of clinical decision support software for alerting providers of a potential stroke	2026-06-03
SRC-008	Viz.ai	Viz.ai closes 2025 with record scale and patient impact	2026-06-03
SRC-009	Viz.ai	Viz.ai leadership page	2026-06-03
SRC-010	Viz.ai	Viz.ai careers page	2026-06-03
SRC-011	Viz.ai	Viz.ai trust center	2026-06-03
SRC-012	Viz.ai	Viz.ai achieves ISO/IEC 42001 certification	2026-06-03
SRC-013	Viz.ai	Viz.ai strategic partners	2026-06-03
SRC-014	Viz.ai	Viz.ai collaborates with Microsoft	2026-06-03
SRC-015	Viz.ai	Viz.ai agreement with Bristol Myers Squibb for HCM	2026-06-03
SRC-016	Viz.ai	Viz.ai receives FDA De Novo approval for HCM algorithm	2026-06-03
SRC-017	Viz.ai	Piedmont Health System implementation case study	2026-06-03
SRC-018	CourtListener	CourtListener API search for Viz.ai	2026-06-03
SRC-019	RapidAI	RapidAI home page	2026-06-03
SRC-020	Aidoc	Aidoc home page	2026-06-03
SRC-021	Qure.ai	Qure.ai home page	2026-06-03
SRC-022	Brainomix	Brainomix home page	2026-06-03
SRC-023	Viz.ai	Viz.ai Our Story	2026-06-03
SRC-024	Viz.ai	Viz.ai launches Viz Pulmonary Suite	2026-06-03
SRC-025	Viz.ai	Viz.ai launches Viz Agent Studio	2026-06-03

Disclaimer

This report is a public-evidence diligence snapshot, not investment advice. Important financial, legal, technical, and contractual facts remain non-public and should be verified directly with management and primary documents before any investment decision.